Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging

被引：55

作者：

Chiang, SB ^{[1
]}

Rebenstock, A ^{[1
]}

Guan, L ^{[1
]}

Alavi, A ^{[1
]}

Zhuang, HM ^{[1
]}

机构：

[1] Hosp Univ Penn, Div Nucl Med, Dept Radiol, Philadelphia, PA 19104 USA

来源：

CLINICAL NUCLEAR MEDICINE | 2003年 / 28卷 / 08期

关键词：

FDG PET; cytokine; Hodgkin lymphoma; bone marrow;

D O I：

10.1097/01.rlu.0000079394.76990.08

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Whole-body fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET) has been useful in the management of a variety of malignancies. In patients with chemotherapy followed by bone marrow stimulants such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, the bone marrow will have diffuse, increased FDG accumulation. Therefore, diffuse bone marrow FDG uptake is commonly attributable to the effect of hematopoietic cytokines. However, diffuse bone marrow FDG uptake can also be caused by bone marrow involvement by malignancy. The authors report a patient with diffuse bone marrow involvement of Hodgkin disease that appears indistinguishable from hematopoietic cytokine-mediated FDG bone marrow uptake.

引用

页码：674 / 676

页数：3

共 9 条

[1] Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation [J].

Abdel-Dayem, HM ;

Rosen, G ;

El-Zeftawy, H ;

Naddaf, S ;

Kumar, M ;

Atay, S ;

Cacavio, A .

CLINICAL NUCLEAR MEDICINE, 1999, 24 (05) :319-322

[2] Detection of lymphoma in bone marrow by whole-body positron emission tomography [J].

Carr, R ;

Barrington, SF ;

Madan, B ;

O'Doherty, MJ ;

Saunders, CAB ;

van der Walt, J ;

Timothy, AR .

BLOOD, 1998, 91 (09) :3340-3346

[3]

Hoh CK, 1997, J NUCL MED, V38, P343

[4] Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging [J].

Hollinger, EF ;

Alibazoglu, H ;

Ali, A ;

Green, A ;

Lamonica, G .

CLINICAL NUCLEAR MEDICINE, 1998, 23 (02) :93-98

[5]

Hueltenschmidt B, 2001, CANCER-AM CANCER SOC, V91, P302, DOI 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO

[6]

2-4

[7] 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution [J].

Partridge, S ;

Timothy, A ;

O'Doherty, MJ ;

Hain, SF ;

Rankin, S ;

Mikhaeel, G .

ANNALS OF ONCOLOGY, 2000, 11 (10) :1273-1279

[8]

Sugawara Y, 1999, J NUCL MED, V40, P1456

[9] Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy [J].

Sugawara, Y ;

Fisher, SJ ;

Zasadny, KR ;

Kison, PV ;

Baker, LH ;

Wahl, RL .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :173-180

← 1 →